Why Calidi Biotherapeutics (CLDI) Stock Is Down 30%
I'm PortAI, I can summarize articles.
Calidi Biotherapeutics (CLDI) shares fell 32% to 92 cents after the company announced a public offering of 5 million shares at $0.85 each, aiming to raise $4.25 million. The offering is expected to close on January 10. Year-to-date, CLDI has dropped 92.85%, significantly underperforming its historical average of -76.04%. The stock's Relative Strength Index is currently at 55.44, indicating neutral market conditions. CLDI's 52-week high is $16.80, and the low is $0.73.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments